AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] BioAtla, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

BioAtla, Inc. (BCAB) â€� Form 4 insider transaction

Director Lawrence Steinman reported the grant of 23,500 shares of common stock in the form of time-based restricted stock units (RSUs) on 18 June 2025. The RSUs will vest 100% on the earlier of (i) 18 June 2026 or (ii) the next annual meeting of stockholders, conditional upon his continued board service.

  • Transaction code: A (award)
  • Transaction price: $0 (equity award, not a market purchase)
  • Post-transaction direct ownership: 78,459 common shares

No derivative securities were reported. The filing indicates routine board compensation designed to align director incentives with shareholder interests and does not signal any open-market buying or selling by the insider.

BioAtla, Inc. (BCAB) � Transazione interna Form 4

Il direttore Lawrence Steinman ha segnalato la concessione di 23.500 azioni ordinarie sotto forma di unità azionarie vincolate basate sul tempo (RSU) in data 18 giugno 2025. Le RSU matureranno al 100% alla prima delle seguenti date: (i) 18 giugno 2026 oppure (ii) la prossima assemblea annuale degli azionisti, a condizione che continui a far parte del consiglio di amministrazione.

  • Codice transazione: A (assegnazione)
  • Prezzo di transazione: $0 (assegnazione azionaria, non un acquisto sul mercato)
  • Proprietà diretta post-transazione: 78.459 azioni ordinarie

Non sono stati segnalati titoli derivati. La comunicazione indica una compensazione ordinaria del consiglio volta ad allineare gli interessi dei direttori con quelli degli azionisti e non segnala alcun acquisto o vendita sul mercato aperto da parte dell'insider.

BioAtla, Inc. (BCAB) � Transacción de insider Formulario 4

El director Lawrence Steinman informó la concesión de 23,500 acciones comunes en forma de unidades restringidas basadas en tiempo (RSU) el 18 de junio de 2025. Las RSU se consolidarán al 100% en la fecha que ocurra primero entre (i) 18 de junio de 2026 o (ii) la próxima junta anual de accionistas, condicionado a que continúe en el consejo.

  • Código de transacción: A (premio)
  • Precio de transacción: $0 (premio de capital, no una compra en el mercado)
  • Propiedad directa post-transacción: 78,459 acciones comunes

No se reportaron valores derivados. La presentación indica una compensación rutinaria del consejo diseñada para alinear los incentivos del director con los intereses de los accionistas y no señala ninguna compra o venta en el mercado abierto por parte del insider.

BioAtla, Inc. (BCAB) � Form 4 내부� 거래 보고

ì´ì‚¬ Lawrence Steinmanì� 2025ë…� 6ì›� 18ì�ì—� 시간 기반 제한 ì£¼ì‹ ë‹¨ìœ„(RSU) 형태ë¡� 23,500ì£� 보통ì£�ë¥� 부여받았다ê³� 보고했습니다. RSUëŠ� (i) 2026ë…� 6ì›� 18ì� ë˜ëŠ” (ii) ë‹¤ìŒ ì—°ë¡€ 주주ì´íšŒ ì¤� 빠른 시ì ì—� 100% 베스팅ë˜ë©�, ì´ì‚¬íš� 서비ìŠ� ì§€ì†ì´ 조건입니ë‹�.

  • 거래 코드: A (수여)
  • 거래 ê°€ê²�: $0 (ì£¼ì‹ ë³´ìƒ, 시장 구매 아님)
  • 거래 í›� ì§ì ‘ 소유: 78,459ì£� 보통ì£�

íŒŒìƒ ì¦ê¶Œì€ ë³´ê³ ë˜ì§€ 않았습니ë‹�. ì� ë³´ê³ ëŠ� ì´ì‚¬ ë³´ìƒì� 통해 ì´ì‚¬ì™€ 주주 ê°� ì´í•´ê´€ê³„를 ì¼ì¹˜ì‹œí‚¤ê¸� 위한 ì¼ìƒì ì¸ ì¡°ì¹˜ìž„ì„ ë‚˜íƒ€ë‚´ë©°, ë‚´ë¶€ìžì˜ 공개 시장 매매ë¥� ì˜ë¯¸í•˜ì§€ 않습니다.

BioAtla, Inc. (BCAB) � Transaction d’initié Formulaire 4

Le directeur Lawrence Steinman a déclaré l’attribution de 23 500 actions ordinaires sous forme d’unités d’actions restreintes basées sur le temps (RSU) le 18 juin 2025. Les RSU seront acquises à 100 % à la première des dates suivantes : (i) 18 juin 2026 ou (ii) la prochaine assemblée annuelle des actionnaires, sous condition qu’il continue à siéger au conseil d’administration.

  • Code de transaction : A (attribution)
  • Prix de la transaction : 0 $ (attribution d’actions, pas un achat sur le marché)
  • Propriété directe après transaction : 78 459 actions ordinaires

Aucun titre dérivé n’a été signalé. Le dépôt indique une rémunération habituelle du conseil visant à aligner les incitations des administrateurs avec les intérêts des actionnaires et ne signale aucune opération d’achat ou de vente sur le marché ouvert par l’initié.

BioAtla, Inc. (BCAB) � Form 4 Insider-Transaktion

Direktor Lawrence Steinman meldete die Gewährung von 23.500 Stammaktien in Form von zeitbasierten Restricted Stock Units (RSUs) am 18. Juni 2025. Die RSUs werden zu 100 % fällig am früheren Zeitpunkt von (i) 18. Juni 2026 oder (ii) der nächsten jährlichen Hauptversammlung, vorausgesetzt, er bleibt im Vorstand.

  • Transaktionscode: A (Zuwendung)
  • Transaktionspreis: 0 $ (Aktienzuwendung, kein Marktkauf)
  • Direktbesitz nach Transaktion: 78.459 Stammaktien

Es wurden keine Derivate gemeldet. Die Meldung deutet auf eine routinemäßige Vergütung des Vorstands hin, die darauf abzielt, die Interessen der Direktoren mit denen der Aktionäre in Einklang zu bringen, und signalisiert keinen Kauf oder Verkauf am offenen Markt durch den Insider.

Positive
  • Director ownership increases to 78,459 shares, modestly tightening management-shareholder alignment
Negative
  • None.

Insights

TL;DR: Routine RSU grant increases director alignment; immaterial to valuation.

The single RSU award is standard annual board compensation. Vesting in one year, contingent on service, supports long-term alignment without immediate cash outlay. The director now holds 78,459 shares, a modest stake that reinforces commitment but poses negligible dilution. No red flags or unusual structures observed.

TL;DR: Neutral market impact; no open-market purchase or sale.

Because the shares are awarded at $0 and represent a small fraction of BioAtla’s outstanding float, the transaction is not expected to influence trading dynamics or valuation. Investors may view the continued accumulation as a mild positive signal, yet the absence of cash investment limits interpretive weight.

BioAtla, Inc. (BCAB) � Transazione interna Form 4

Il direttore Lawrence Steinman ha segnalato la concessione di 23.500 azioni ordinarie sotto forma di unità azionarie vincolate basate sul tempo (RSU) in data 18 giugno 2025. Le RSU matureranno al 100% alla prima delle seguenti date: (i) 18 giugno 2026 oppure (ii) la prossima assemblea annuale degli azionisti, a condizione che continui a far parte del consiglio di amministrazione.

  • Codice transazione: A (assegnazione)
  • Prezzo di transazione: $0 (assegnazione azionaria, non un acquisto sul mercato)
  • Proprietà diretta post-transazione: 78.459 azioni ordinarie

Non sono stati segnalati titoli derivati. La comunicazione indica una compensazione ordinaria del consiglio volta ad allineare gli interessi dei direttori con quelli degli azionisti e non segnala alcun acquisto o vendita sul mercato aperto da parte dell'insider.

BioAtla, Inc. (BCAB) � Transacción de insider Formulario 4

El director Lawrence Steinman informó la concesión de 23,500 acciones comunes en forma de unidades restringidas basadas en tiempo (RSU) el 18 de junio de 2025. Las RSU se consolidarán al 100% en la fecha que ocurra primero entre (i) 18 de junio de 2026 o (ii) la próxima junta anual de accionistas, condicionado a que continúe en el consejo.

  • Código de transacción: A (premio)
  • Precio de transacción: $0 (premio de capital, no una compra en el mercado)
  • Propiedad directa post-transacción: 78,459 acciones comunes

No se reportaron valores derivados. La presentación indica una compensación rutinaria del consejo diseñada para alinear los incentivos del director con los intereses de los accionistas y no señala ninguna compra o venta en el mercado abierto por parte del insider.

BioAtla, Inc. (BCAB) � Form 4 내부� 거래 보고

ì´ì‚¬ Lawrence Steinmanì� 2025ë…� 6ì›� 18ì�ì—� 시간 기반 제한 ì£¼ì‹ ë‹¨ìœ„(RSU) 형태ë¡� 23,500ì£� 보통ì£�ë¥� 부여받았다ê³� 보고했습니다. RSUëŠ� (i) 2026ë…� 6ì›� 18ì� ë˜ëŠ” (ii) ë‹¤ìŒ ì—°ë¡€ 주주ì´íšŒ ì¤� 빠른 시ì ì—� 100% 베스팅ë˜ë©�, ì´ì‚¬íš� 서비ìŠ� ì§€ì†ì´ 조건입니ë‹�.

  • 거래 코드: A (수여)
  • 거래 ê°€ê²�: $0 (ì£¼ì‹ ë³´ìƒ, 시장 구매 아님)
  • 거래 í›� ì§ì ‘ 소유: 78,459ì£� 보통ì£�

íŒŒìƒ ì¦ê¶Œì€ ë³´ê³ ë˜ì§€ 않았습니ë‹�. ì� ë³´ê³ ëŠ� ì´ì‚¬ ë³´ìƒì� 통해 ì´ì‚¬ì™€ 주주 ê°� ì´í•´ê´€ê³„를 ì¼ì¹˜ì‹œí‚¤ê¸� 위한 ì¼ìƒì ì¸ ì¡°ì¹˜ìž„ì„ ë‚˜íƒ€ë‚´ë©°, ë‚´ë¶€ìžì˜ 공개 시장 매매ë¥� ì˜ë¯¸í•˜ì§€ 않습니다.

BioAtla, Inc. (BCAB) � Transaction d’initié Formulaire 4

Le directeur Lawrence Steinman a déclaré l’attribution de 23 500 actions ordinaires sous forme d’unités d’actions restreintes basées sur le temps (RSU) le 18 juin 2025. Les RSU seront acquises à 100 % à la première des dates suivantes : (i) 18 juin 2026 ou (ii) la prochaine assemblée annuelle des actionnaires, sous condition qu’il continue à siéger au conseil d’administration.

  • Code de transaction : A (attribution)
  • Prix de la transaction : 0 $ (attribution d’actions, pas un achat sur le marché)
  • Propriété directe après transaction : 78 459 actions ordinaires

Aucun titre dérivé n’a été signalé. Le dépôt indique une rémunération habituelle du conseil visant à aligner les incitations des administrateurs avec les intérêts des actionnaires et ne signale aucune opération d’achat ou de vente sur le marché ouvert par l’initié.

BioAtla, Inc. (BCAB) � Form 4 Insider-Transaktion

Direktor Lawrence Steinman meldete die Gewährung von 23.500 Stammaktien in Form von zeitbasierten Restricted Stock Units (RSUs) am 18. Juni 2025. Die RSUs werden zu 100 % fällig am früheren Zeitpunkt von (i) 18. Juni 2026 oder (ii) der nächsten jährlichen Hauptversammlung, vorausgesetzt, er bleibt im Vorstand.

  • Transaktionscode: A (Zuwendung)
  • Transaktionspreis: 0 $ (Aktienzuwendung, kein Marktkauf)
  • Direktbesitz nach Transaktion: 78.459 Stammaktien

Es wurden keine Derivate gemeldet. Die Meldung deutet auf eine routinemäßige Vergütung des Vorstands hin, die darauf abzielt, die Interessen der Direktoren mit denen der Aktionäre in Einklang zu bringen, und signalisiert keinen Kauf oder Verkauf am offenen Markt durch den Insider.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
STEINMAN LAWRENCE

(Last) (First) (Middle)
C/O BIOATLA, INC. 11085 TORREYANA ROAD

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BioAtla, Inc. [ BCAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 23,500(1) A $0 78,459 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.
/s/ Christian Vasquez, as Attorney-in-Fact for Lawrence Steinman 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BioAtla (BCAB) shares did Lawrence Steinman acquire?

He was granted 23,500 restricted stock units representing the same number of common shares.

When will the RSUs granted to Steinman vest?

The RSUs vest 100% on the earlier of 18 Jun 2026 or the next annual meeting, subject to continued service.

What is Steinman’s total BioAtla share ownership after the transaction?

Following the award, he directly owns 78,459 common shares.

Was there any cash paid for the shares in this Form 4 filing?

No. The RSUs were awarded at $0 as part of director compensation; no market purchase occurred.

Did the filing disclose any derivative securities for Steinman?

No derivative securities were reported in Table II.
Bioatla, Inc.

NASDAQ:BCAB

BCAB Rankings

BCAB Latest News

BCAB Latest SEC Filings

BCAB Stock Data

21.91M
51.91M
9.65%
52.35%
5.47%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SAN DIEGO